$RSHN Some food for thought. Current revenues pre-acquisition are estimated at $6 million. Using a standard average rate of 10x, we are looking at about a $60 million market cap, with a PPS of $0.0077. We got up to $0.0080 on Monday, putting us in the general ballpark of aforementioned price. Post-acquisition of lab #1, using the standard 10x rate, we are looking at revenues of approximately $15-$20 million combined by years end. This puts us at about a $175 million market cap, with a PPS of $0.0225. This equates to an increase of over 500% (506.47%) compared to the current PPS of $0.00445. This is not even factoring in any other future acquisitions at all or additional revenues as expected post Q1 Spend as mentioned by the CEO recently. And the 10x rate in the medical field is a very conservative multiple for market cap estimates IMHO. I am by NO MEANS an expert or even seasoned trader, this is just my take on the matter. Thoughts anyone?
5
5